AddLife signs agreement to represent Leica Biosystems operations in Sweden and Denmark

AddLife today signed an agreement to represent Leica Biosystems for all sales and service functions in Sweden and Denmark. The business will become an integral part of existing operations within the business area Labtech.

Leica Biosystems is a global leader in workflow solutions and automation, striving to
advance cancer research and diagnostics to improve patients’ lives. Leica Biosystems provides a comprehensive product range for each step in the pathology process, from sample
preparation and staining to imaging and reporting. Customers are primarily in health care and research laboratories. The business will transfer in May 2016. Leica Biosystems has a turnover of approximately SEK 50 million in Sweden and Denmark

The activities will be built around the strong service and support organization in place in the Triolab companies in the business area Labtech.

- It is gratifying that AddLife had the opportunity for this collaboration with Leica Biosystems. The combination of our existing strong service organization with the expertise and high-quality product portfolio offered by Leica Biosystems enables a better total solution for the customer, says Artur Aira, COO AddLife AB.

The addition of the operations is estimated to have a marginally positive impact on AddLifes earnings per share.

Stockholm April 4 2016

AddLife AB (publ)

For further information contact:
Kristina Willgård, CEO, AddLife AB, +46 705 10 12 23
Artur Aira, COO, AddLife AB, +46 709 50 00 90

AddLife is an independent player in the Life Science sector, offering high-quality products, services and advice to the private and public sectors, above all in the Nordic region. AddLife has about 425 employees in some 25 subsidiaries that operate under their own brands. The Group has annual sales of about SEK 1.7 billion. Addlife shares are listed on NASDAQ Stockholm.

This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ Stockholm. The information was provided for publication at 12.00 noon (CET) on 4 April 2016.